top of page
Clear Scientific News
Search
FDA Grants Fast Track Designation for CS-1103, a First-in-class Small Molecule to Reverse Acute Intoxication from Fentanyl
Cambridge, MA | May 2026 PRNewswire/ -- Clear Scientific Inc., a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted its lead asset, CS-1103, Fast Track designation for treatment of acute fentanyl intoxication. Clear Scientific is focused on the development of first-in-class small molecules to reverse acute intoxication from drugs of abuse and accelerate their clearance from the body, preventing further har
May 5
FDA Grants Fast Track Designation for CS-1103, a First-in-class Small Molecule to Reverse Acute Intoxication from Methamphetamine
Cambridge, MA | September 2025 PRNewswire/ -- Clear Scientific Inc., a clinical stage biopharmaceutical company focused on the development of first-in-class small molecules to reverse acute intoxication from methamphetamine, announced today that the U.S. Food and Drug Administration (FDA) has granted its lead asset, CS-1103, Fast Track designation for treatment of acute methamphetamine intoxication. The FDA grants investigational medicines Fast Track designation to facilitat
Sep 30, 2025
bottom of page